Acerus Pharmaceuticals Corporation ASPCF
0.22 0.00 (+0.00%)
Jan 12, 2023, 9:53 AM EST
0.21988 Day range 0.21988
0.21988 52-week range 8.16
- Volume
- 500
- Avg volume
- 69
- Open
- 0.21988
- Previous close
- 0.21988
- Day's range
- 0.21988 – 0.21988
- 52-week range
- 0.21988 – 8.16
- Earnings date
- Mar 13, 2023
No chart data for this range yet.
Next earnings
Mar 13, 2023
Expected Mar 13, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 13, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
| May 10, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Mar 14, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 8, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
News
China Pharma (NYSE:CPHI) & Acerus Pharmaceuticals (OTCMKTS:ASPCF) Financial Comparison 
Critical Review: Acerus Pharmaceuticals (OTCMKTS:ASPCF) vs. Zymeworks (NASDAQ:ZYME) 
Acerus Update 
Acerus Pharmaceuticals Corporation (ASPCF) CEO Edward Gudaitis on Q2 2022 Results - Earnings Call Transcript 
Acerus to Report Q2-2022 Financial Results and Host Investor Call 
Acerus To Report Q4 And Full Year 2021 Financial Results And Host Investor Call 
Acerus Pharmaceuticals Corporation (ASPCF) CEO Ed Gudaitis on Q3 2021 Results - Earnings Call Transcript 
Acerus to Report Q3-2021 Financial Results and Host Investor Call 
Acerus Announces Participation in HC Wainwright Conference 
Acerus Reports Acceptance of Part 36 Settlement Offer in Recipharm Litigation
Your note
Sign in to keep a note on ASPCF — it syncs with the Stock Master app.